These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 27338084)

  • 1. Improving the power of clinical trials of rheumatoid arthritis by using data on continuous scales when analysing response rates: an application of the augmented binary method.
    Wason JM; Jenkins M
    Rheumatology (Oxford); 2016 Oct; 55(10):1796-802. PubMed ID: 27338084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points.
    Mack ME; Hsia E; Aletaha D
    Arthritis Rheumatol; 2017 Mar; 69(3):518-528. PubMed ID: 27696724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
    Genovese MC; Kavanaugh A; Weinblatt ME; Peterfy C; DiCarlo J; White ML; O'Brien M; Grossbard EB; Magilavy DB
    Arthritis Rheum; 2011 Feb; 63(2):337-45. PubMed ID: 21279990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
    Weinblatt ME; Kavanaugh A; Genovese MC; Musser TK; Grossbard EB; Magilavy DB
    N Engl J Med; 2010 Sep; 363(14):1303-12. PubMed ID: 20879879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritis.
    Schmitz S; Adams R; Walsh C
    BMC Med Res Methodol; 2012 Nov; 12():167. PubMed ID: 23130635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etanercept for the treatment of rheumatoid arthritis.
    Lethaby A; Lopez-Olivo MA; Maxwell L; Burls A; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2013 May; 2013(5):CD004525. PubMed ID: 23728649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Weinblatt ME; Genovese MC; Ho M; Hollis S; Rosiak-Jedrychowicz K; Kavanaugh A; Millson DS; Leon G; Wang M; van der Heijde D
    Arthritis Rheumatol; 2014 Dec; 66(12):3255-64. PubMed ID: 25223724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes.
    Ibrahim F; Tom BD; Scott DL; Prevost AT
    Trials; 2016 Jun; 17(1):272. PubMed ID: 27255212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab for treating rheumatoid arthritis.
    Navarro-Sarabia F; Ariza-Ariza R; Hernandez-Cruz B; Villanueva I
    Cochrane Database Syst Rev; 2005 Jul; (3):CD005113. PubMed ID: 16034967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
    Clark W; Jobanputra P; Barton P; Burls A
    Health Technol Assess; 2004 May; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.
    Anderson JJ; Bolognese JA; Felson DT
    Arthritis Rheum; 2003 Nov; 48(11):3031-8. PubMed ID: 14613263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the analysis of composite endpoints in rare disease trials.
    McMenamin M; Berglind A; Wason JMS
    Orphanet J Rare Dis; 2018 May; 13(1):81. PubMed ID: 29788976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations.
    Boers M
    Arthritis Rheum; 2011 Feb; 63(2):329-30. PubMed ID: 21279987
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.
    Weinblatt ME; Kavanaugh A; Genovese MC; Jones DA; Musser TK; Grossbard EB; Magilavy DB
    J Rheumatol; 2013 Apr; 40(4):369-78. PubMed ID: 23378467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.
    Anderson JJ; Wells G; Verhoeven AC; Felson DT
    Arthritis Rheum; 2000 Jan; 43(1):22-9. PubMed ID: 10643696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.
    Bingham CO; Gaich CL; DeLozier AM; Engstrom KD; Naegeli AN; de Bono S; Banerjee P; Taylor PC
    Trials; 2019 Mar; 20(1):182. PubMed ID: 30902094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials.
    Pham B; Cranney A; Boers M; Verhoeven AC; Wells G; Tugwell P
    J Rheumatol; 1999 Mar; 26(3):712-6. PubMed ID: 10090188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis.
    Nijjar JS; Tindell A; McInnes IB; Siebert S
    Rheumatology (Oxford); 2013 Sep; 52(9):1556-62. PubMed ID: 23861534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
    Ruiz Garcia V; Burls A; Cabello JB; Vela Casasempere P; Bort-Marti S; Bernal JA
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD007649. PubMed ID: 28884785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.